Department of Systems Medicine, Internal Medicine-Center of Hypertension and Nephrology Unit, Tor Vergata University, Rome, Italy.
PhD School of Applied Medical-Surgical Sciences, Tor Vergata University, Rome, Italy.
Curr Pharm Biotechnol. 2019;20(5):366-375. doi: 10.2174/1389201020666190417124711.
Fenoldopam mesylate is a selective agonist of DA-1 receptors. It is currently used for the in-hospital treatment of severe hypertension. DA-1 receptors have high density in renal parenchyma and for this reason, a possible reno-protective role of Fenoldopam mesylate was investigated.
We examined all studies regarding the role of Fenoldopam mesylate in Acute Kidney Injury (AKI); particularly, those involving post-surgical patients, intensive care unit patients and contrastinduced nephropathy.
Fenoldopam mesylate was found to be effective in reducing the onset of postoperative AKI, when used before the development of the kidney damage. Positive results were also obtained in the management of intensive care unit patients with AKI, although the clinical studies investigated were few and conducted on small samples.
Conflicting results were achieved in contrast-induced nephropathy.
甲磺酸酚妥拉明是一种 DA-1 受体的选择性激动剂。它目前被用于院内严重高血压的治疗。DA-1 受体在肾实质中具有高密度，因此研究了甲磺酸酚妥拉明的可能的肾保护作用。
我们检查了所有关于甲磺酸酚妥拉明在急性肾损伤（AKI）中的作用的研究；特别是那些涉及手术后患者、重症监护病房患者和造影剂肾病的研究。
甲磺酸酚妥拉明在肾损伤发生前使用时，可有效降低术后 AKI 的发生。在 AKI 重症监护病房患者的治疗中也取得了阳性结果，尽管研究的临床研究较少且样本较小。
在造影剂肾病中得出了相互矛盾的结果。
